UNILABS
- EBITDA: €33m, organic growth rate of 20.1% at constant exchange rates (CER)
- Free cash flow: €12.4m
- Cost savings1) : €4.9m
- Strong organic growth in the Laboratory segment: 5.1%
-
2016 Guidance confirmed:
- Organic sales growth of 4-5% (CER)
- Organic EBITDA growth of 8-12% (CER)
- Positive cash flow before M&A
1) Cost Leadership Initiative (CLS)
Unilabs Group reports a strong second quarter performance for 2016. Commenting on the results, Jos Lamers, Chief Executive Officer stated, “Our continued focus on generating profitable organic top-line growth combined with a strong focus on optimising our cost base has allowed us to deliver another quarter of solid EBITDA growth. Building on this momentum we see a healthy pipeline of commercial opportunities in the second half of the year.”
Medical diagnostics continue to play an increasingly important role in a steadily growing healthcare market. With a shifting focus from treatment to prediction and prevention, medical diagnostics contributes to reducing the cost pressure on healthcare systems and provides a favourable market outlook for Unilabs.
Financial highlights of Q2:
Unilabs Group | |||||||||||||||||||||||
€millions |
Q2 Reported |
Q2 CER |
YTD | YTD CER | |||||||||||||||||||
2015 | 2016 | % change | 2016 CER | % change | 2015 | 2016 | % change | 2016 CER | % change | ||||||||||||||
Revenues | 172.1 | 176.1 | 2.3% | 180.3 | 4.8% | 339.7 | 348 | 2.4% | 354.4 | 4.3% | |||||||||||||
Adjusted EBITDA | 27.2 | 32.2 | 18.5% | 33 | 21.4% | 53.7 | 61.3 | 14.1% | 62.5 | 16.3% | |||||||||||||
Adjusted EBITDA margin | 15.8% | 18.3% | 250 bps | 18.3% | 251 bps | 15.8% | 17.6% | 180 bps | 17.60% | 181 bps | |||||||||||||
Free cash flow | 20.6 | 12.4 | -39.8% | 12.4 | -39.8% | 32.5 | 37.7 | 16.1% | 37.7 | 16.1% | |||||||||||||
Organic revenues (a) | 171.4 | 174.4 | 1.8% | 178.6 | 4.2% | 338.2 | 343.7 | 1.6% | 350.2 | 3.6% | |||||||||||||
Organic Adjusted EBITDA (b) | 27.1 | 31.8 | 17.3% | 32.6 | 20.1% | 53.7 | 60.5 | 12.6% | 61.7 | 14.8% |
(a)Excludes acquisitions made within the prior 12 months
(b)Excludes acquisitions made within the prior 12 months; Adjusted for non-recurring, restructuring/acq. Costs
Delivering continued organic growth (Organic Growth Initiative – OGROW) :
Unilabs has delivered increased organic growth in net sales of 4.2% CER (1.8% reported) and organic EBITDA growth up by 20.1% CER (17.3% reported) on a like for like basis.
These results are attributable to a strong performance in nearly all markets, led by France (Chemistry & Pathology ), Switzerland (positive development of key accounts), Sweden (strong volume growth) and Pathology (Nordics, France, Portugal & Switzerland) in particular.
The Laboratory segment performed particularly well with France, Norway and Sweden by generating high organic volume growth.
In the Imaging segment, the new tender wins will start to contribute to growth in the third quarter onwards.
Optimising our cost structure (Cost Leadership Initiative - CLS) :
The CLS delivered savings of €4.9M for the second quarter for a total of €8.5M year to date. The combination of constant revenue growth and excellent results from our CLS initiative contributed to the substantial growth of EBITDA margins.
“Eight consecutive quarters of growth have also allowed us to be more active in pursuing our inorganic growth strategy. Since mid-2015 we have carefully vetted a number of M&A opportunities that are aligned with our growth ambitions and would also create sustainable shareholder value. Consequently, we are in advanced discussions towards finalising a mid-sized deal still this year”, said Jos Lamers.
2016 Guidance:
Commenting on Unilabs’ 2016 guidance, Karl Erik Clausen, Chief Financial Officer said, “With favourable market perspectives and building on the solid foundations of our HY1 financials, we confirm our 2016 guidance provided earlier this year”.
- Confirmed: 4-5% organic sales growth (CER)
- Confirmed: EBITDA growth of 8-12% (CER)
- Confirmed: Positive cash-flow before mergers & acquisitions
- ENDS -
NOTES TO EDITORS:
- The importance of medical diagnostics is expanding; aging populations and increase of chronic diseases lead to increased investment in healthcare infrastructure and expenditure. And as the focus shifts from treatment to prediction and prevention, and innovations in molecular and genetic testing continue to emerge, Unilabs aims to be at the heart of this healthcare transformation.
- Effective diagnostics contribute to 70% of all treatment decisions and are at the basis of 100% of cancer diagnoses, but at only 3% of healthcare costs1 .
- Unilabs mediates care. In 2015 , its laboratories carried out over 109 million diagnostic tests ensuring swift, accurate diagnosis of patient samples, 5,000 IVF procedures and over 1.4 million radiology exams.
1 Lewin Group study, “The Value of Diagnostics Innovation, Adoption and Diffusion into Health Care”, 2005
About Unilabs
With over 112 laboratories and 43 imaging units and a broad catalogue of more than 2,500 diagnostic tests, Unilabs is one of Europe’s leading providers of clinical laboratory testing and medical diagnostic imaging services. Headquartered in Geneva, the Unilabs Group services sectors ranging from private and public healthcare providers to local governments, from pharmaceutical companies to the general public. The Unilabs Group employs more than 5,200 people worldwide, internationally successfully operating laboratory and medical diagnostic imaging facilities in 12 countries, generating annual revenues of €673m in 2015. Its network of facilities provides its customers with one of the broadest geographic footprints of any clinical laboratory and medical diagnostic services provider in Europe.
We are at the heart and start of all effective treatment decisions - www.unilabs.com
Forward Looking Statement
This press release contains various “forward-looking statements” that reflect management’s current view with respect to future events and anticipated financial and operational performance. Forward-looking statements as a general matter are all statements other than statements as to historical fact or present facts or circumstances. The words “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “guidance,” “intend,” “may,” “plan,” “potential,” “predict,” “projected,” “risk,” “should,” “will” and similar expressions or the negatives of these expressions are intended to identify forward-looking statements. Other forward-looking statements can be identified in the context in which the statements are made. These forward-looking statements may include, among other things, statements relating to: our future financial position; our strategy and outlook; our liquidity, capital resources and capital expenditure; our planned investments; acquisition opportunities in the markets in which we currently, or may in the future, operate; expectations as to future growth in demand for our products and services; demographic trends; general economic trends and other trends in our industry; the impact of regulations on us and our operations; the competitive environment in which we operate; the outcome of legal proceedings; extreme weather conditions in the markets where we operate; failure to comply with privacy laws; and failure to comply with environmental health and safety laws. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can provide no assurances that such expectations will prove to be correct and such statements are not guarantees of future performance because they are based on numerous assumptions. Forward-looking statements are based on information available at the time those statements are made and management's good faith belief as of that time with respect to future events and are subject to known and unknown risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a further discussion of such risks please see the risks discussed under the caption “Risk Factors” beginning on page 26 of the Offering Memorandum dated July 10, 2013 (the “OM”) in connection with our offering of senior secured notes and second lien PIK toggle notes (collectively, the “Notes”). You should not place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as at the date on which it is made and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160830005030/en/
Contact:
For Unilabs
Clark Health Communications
Sophie Dyer
+44
(0)20 7492 1900
unilabs@clarkhealthcomms.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance Welcomes Global Technology Leaders as Licensees and Licensors to New Video Distribution Patent Pool2.7.2025 02:00:00 CEST | Press release
Access Advance LLC ("Advance") today announced the inaugural roster of licensees and licensors for its Video Distribution Patent ("VDP") Pool, marking a significant milestone in the program's rapid market adoption since its January announcement. The participation of major global companies heavily involved in video codec technology demonstrates strong industry support for the comprehensive licensing solution covering HEVC, VVC, VP9, and AV1 codecs. The VDP Pool has successfully attracted a group of licensees/licensors including ByteDance, Kuaishou, NTT Docomo, and Tencent. This represents the beginning of what Access Advance expects to be widespread adoption among content streaming providers seeking simplified codec licensing. The licensees’ participation provides immediate access to the wide-ranging patent portfolio while benefiting from the fixed tiered pricing structure designed to scale with business size. "We're pleased to welcome ByteDance, Kuaishou, NTT Docomo and Tencent as our
Intralot S.A. to Acquire Bally’s International Interactive Business in a Transaction that Creates a Global Gaming Technology and Services Company in Lottery and Digital Online Gaming Markets1.7.2025 21:10:00 CEST | Press release
Intralot S.A. to Remain Listed on the Athens Stock ExchangeTransaction Enterprise Value of €2.7 Billion Intralot S.A. (ATSE: INLOT) (“Intralot”) and Bally’s Corporation (NYSE: BALY) (“Bally’s”) today announced that their respective Boards of Directors approved their entry into a definitive transaction agreement (“Transaction Agreement”) pursuant to which Intralot will acquire Bally’s International Interactive business (the “International Interactive Business”) in a cash-and-shares transaction that values the International Interactive Business at an enterprise value of €2.7 billion (the “Transaction”). The consideration for the acquisition of the International Interactive Business will comprise a combination of cash paid by Intralot and newly issued shares delivered by Intralot to Bally’s, as more specifically detailed below. As part of the Transaction, Intralot expects to refinance part of its existing debt facilities and Bally’s also expects to repay secured debt from the cash proceed
Valeo Foods Group Acquires Melegatti Cakes Expanding the Italian Bakery Portfolio1.7.2025 18:21:00 CEST | Press release
Valeo Foods Group, one of Europe’s leading producers of quality sweets, treats and snacks, has successfully acquired the assets of an Italian panettone, pandoro and croissant producer, Melegatti 1894 S.p.A.This acquisition is another step forward in Valeo Foods Groups’ strategy to expand its baked sweet treats portfolio, and reinforces Valeo’s commitment to bringing authentic Italian confections and established regional brands to a wider international audience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702677156/en/ Melegatti Founded in 1894 in Verona, Melegatti has a strong reputation for artisanal cakes - particularly pandoro, panettone and filled croissants - traditional recipes, and a rich Italian heritage, Melegatti has a proud legacy founded on family values, craftsmanship, and a passion for quality. “We are excited to welcome Melegatti into the Valeo Foods Group,” said Ronald Kers, Group CEO. “This acquisition
PUMA and Borussia Dortmund Extend Partnership1.7.2025 18:18:00 CEST | Press release
Sports company PUMA has extended its long-standing partnership with Borussia Dortmund, and will continue to create products that cater to BVB’s many passionate fans around the world and match the club’s dynamic, fast paced style of football. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701775493/en/ Sports company PUMA has extended its long-standing partnership with Borussia Dortmund, and will continue to create products that cater to BVB’s many passionate fans around the world and match the club’s dynamic, fast paced style of football. Since the start of their partnership in the 2012/13 season, BVB has celebrated many successes, such as reaching the finals of the 2012/13 and 2023/24 UEFA Champions League and winning the 2016/17 and 2020/21 German DFB Cup. The club is currently participating in the FIFA Club World Cup, where it has already reached the round of 16. BVB continues to set the standard in European football w
Gogo Galileo HDX Coming to Cessna Citation Jet Models1.7.2025 17:00:00 CEST | Press release
Expected FAA Supplemental Type Certification in late 2025 Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced Gogo Galileo HDX will be available for aftermarket installation on Cessna Citation jets after Federal Aviation Administration (FAA) Supplemental Type Certification (STC) expected in late 2025. The global Low Earth Orbit (LEO) solution allows customers to enjoy one of the best possible in-flight connectivity and aviation experiences, no matter where their journey takes them. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701750049/en/ Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced Gogo Galileo HDX will be available for aftermarket installation on Cessna Citation jets after Federal Aviation Administration (FAA) Supplemental Type Certification (STC) expected in late 2025. (Photo: Textron Aviation) By offering Gogo Galileo HDX as an aftermarket upgrade, the Textron Av
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom